

8. R&D Pipeline

	Stage	Theme	Target	Dosage Form	Characteristics	Next Step
1	Approved	XELSTRYM(ATS)	USA	Patch	Attention Deficit Hyperactivity Disorder (ADHD)	To be launched in FY22
2	Approved	HP-3150	JPN	Patch	Low back pain Humeroscapular periarthritis Cervico-omo-brachial syndrome Tenosynovitis	Approved on Jun. xxth, FY22
3	Filed	HP-5070	JPN	Transdermal	Primary palmar hyperhidrosis	To be approved in FY23
4	Phase3	HP-5000	USA	Patch	Osteoarthritis of the knee	To be filed in FY23

※Yellow-highlighted parts are changes from the previous announcement made on Apr.7th,2022